Skip to content

Integrated Care Pathway in Oncology (PASSION)

Integrated Management of Care Pathway in Oncology. Impact on the Delay of Therapeutic Management and the Satisfaction of Patients and Carers

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04235556
Acronym
PASSION
Enrollment
1800
Registered
2020-01-22
Start date
2020-02-21
Completion date
2022-12-31
Last updated
2022-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Thoracic Neoplasms

Keywords

care pathway, satisfaction, oncology, treatment delay

Brief summary

A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...). The aim of this study is to assess the delay between the first appointment with the oncologist and the beginning of the antitumoral treatment, and therefore evaluate the efficacy of the care pathway unit. The second aim is to assess the satisfaction of patients and health care teams.

Detailed description

PASSION is a french monocentric study. For the retrospective cohort, patient will be selected through the use of data warehouse available on the HEGP. For the prospective cohort, patient will be included according to the selection criteria. Each patient will be followed up during 6 month and a satisfaction questionnaire will be completed at 1 month and 4 month of the first administration of anti-tumor therapy. For both cohort, clinical-anatomo-biological data will be collected through the use of data warehouse available on the HEGP.

Interventions

BEHAVIORALCare pathway unit

Patients from the prospective cohort will have their health care scheduled by the care pathway unit.

Sponsors

MSD France
CollaboratorINDUSTRY
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Histologically proven : colon, gastric, pancreatic, prostate, bladder, breast, thoracic, or ovarian cancer * First appointment for cancer care at the Hôpital Européen Georges Pompidou * Intravenous antitumoral treatment

Exclusion criteria

* Medical care non covered by social welfare * Radiochemotherapy * Death in the 6 months following first oncological appointment or absence of medical care in the year following the first oncological appointment

Design outcomes

Primary

MeasureTime frameDescription
Time between the first appointment with the oncologist and the beginning of antitumoral treatment.6 monthsDelay of health care

Secondary

MeasureTime frameDescription
Patients satisfaction6 monthsSatisfaction of patients with OUT-PATSAT35 questionnaire (out-patient satisfaction) : Likert type scale with 5 ordered modalities (bad to excellent), rated from 1 to 5.
Health care teams satisfaction6 monthsSatisfaction of health care teams : qualitative questionnaire with 4 ordered modalities (very satisfied to not satisfied)
Rate of emergency consultations and hospitalizations6 monthsNeed for unexpected health care

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026